DOYLESTOWN, Pa., Nov. 24, 2014 (GLOBE NEWSWIRE) -- OnCore Biopharma, Inc. announced today that it has confidentially submitted a draft registration statement to the U.S. Securities and Exchange Commission for a proposed initial public offering of its common stock. The date of the proposed offering and the number and price of the shares of common stock to be offered have not yet been determined.
This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933, as amended. As required by Rule 135, this press release is not an offer to sell or a solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.
CONTACT: Patrick T. Higgins, CEO firstname.lastname@example.org
Source:OnCore Biopharma, Inc.